Cardiovascular effects of antimuscarinic agents and beta3-adrenergic receptor agonist for the treatment of overactive bladder

Vibegron, a Novel Potent and Selective β 3 -Adrenoreceptor Agonist, for the Treatment of Patients with Overactive Bladder: A Randomized, Double-blind, Placebo-controlled Phase 3 Study

(2018) Masaki Yoshida et al.   EUROPEAN UROLOGY

2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction

(2018) Clyde W. Yancy et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add-on mirabegron therapy to solifenacin (BESIDE)

(2017) Marcus J. Drake et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

An Exploratory Study in Healthy Male Subjects of the Mechanism of Mirabegron-Induced Cardiovascular Effects

(2017) Marcel van Gelderen et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Patient-reported outcomes from SYNERGY, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with monotherapy and placebo in OAB patients

(2017) Dudley Robinson et al.   NEUROUROLOGY AND URODYNAMICS

Translational science approach for assessment of cardiovascular effects and proarrhythmogenic potential of the beta-3 adrenergic agonist mirabegron

(2017) Cees Korstanje et al.   JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS

The efficacy and tolerability of mirabegron in a non-trial clinical setting

(2016) Aswini Balachandran et al.   European Journal of Obstetrics & Gynecology and Reproductive Biology

Cardiovascular Safety of β3-adrenoceptor Agonists for the Treatment of Patients with Overactive Bladder Syndrome

(2016) Gian Marco Rosa et al.   EUROPEAN UROLOGY

Real-world cardiovascular assessment of mirabegron treatment in patients with overactive bladder and concomitant cardiovascular disease: Results of a Japanese post-marketing study

(2016) Takao Katoh et al.   INTERNATIONAL JOURNAL OF UROLOGY

Pharmacological Characterization of a Novel Beta 3 Adrenergic Agonist, Vibegron: Evaluation of Antimuscarinic Receptor Selectivity for Combination Therapy for Overactive Bladder

(2016) J. Di Salvo et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

β3-Adrenoceptor agonists for overactive bladder syndrome: Role of translational pharmacology in a repositioning clinical drug development project

(2016) Martin C. Michel et al.   PHARMACOLOGY & THERAPEUTICS

Use of FDSS/μCell imaging platform for preclinical cardiac electrophysiology safety screening of compounds in human induced pluripotent stem cell-derived cardiomyocytes

(2016) Haoyu Zeng et al.   JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS

Safety and efficacy of mirabegron as ‘add-on’ therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study)

(2015) Osamu Yamaguchi et al.   BJU INTERNATIONAL

Combination Treatment with Mirabegron and Solifenacin in Patients with Overactive Bladder: Efficacy and Safety Results from a Randomised, Double-blind, Dose-ranging, Phase 2 Study (Symphony)

(2015) Paul Abrams et al.   EUROPEAN UROLOGY

Frequently occurring Torsades de pointes attacks in an old patient on solifenacin therapy and management strategy

(2015) Namik Ozmen et al.   Anatolian Journal of Cardiology

Phase III, randomised, double-blind, placebo-controlled study of the β3-adrenoceptor agonist mirabegron, 50 mg once daily, in Japanese patients with overactive bladder

(2014) Osamu Yamaguchi et al.   BJU INTERNATIONAL

Mechanisms of Plaque Formation and Rupture

(2014) Jacob Fog Bentzon et al.   CIRCULATION RESEARCH

Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder in Asia

(2014) Hann-Chorng Kuo et al.   NEUROUROLOGY AND URODYNAMICS

Adrenergic signaling in heart failure: a balance of toxic and protective effects

(2014) Anthony J. Baker   PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY

Pharmacokinetics of Mirabegron, a β3-Adrenoceptor Agonist for Treatment of Overactive Bladder, in Healthy Japanese Male Subjects: Results from Single- and Multiple-Dose Studies

(2013) Hiromi Iitsuka et al.   CLINICAL DRUG INVESTIGATION

The pharmacokinetic evaluation of mirabegron as an overactive bladder therapy option

(2013) Mahendra Kashyap et al.   Expert Opinion on Drug Metabolism & Toxicology

Cardiovascular effects of antimuscarinic agents in overactive bladder

(2013) Gian Marco Rosa et al.   Expert Opinion On Drug Safety

Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies

(2013) V. W. Nitti et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

A phase II dose-ranging study of mirabegron in patients with overactive bladder

(2013) Christopher R. Chapple et al.   INTERNATIONAL UROGYNECOLOGY JOURNAL

A proof-of-concept study: Mirabegron, a new therapy for overactive bladder

(2013) Christopher R. Chapple et al.   NEUROUROLOGY AND URODYNAMICS

Mirabegron in overactive bladder: A review of efficacy, safety, and tolerability

(2013) Christopher R. Chapple et al.   NEUROUROLOGY AND URODYNAMICS

Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience

(2012) Adrian Wagg et al.   BJU INTERNATIONAL

Proarrhythmic Safety of Repeat Doses of Mirabegron in Healthy Subjects: A Randomized, Double-Blind, Placebo-, and Active-Controlled Thorough QT Study

(2012) M Malik et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Randomized Double-blind, Active-controlled Phase 3 Study to Assess 12-Month Safety and Efficacy of Mirabegron, a β3-Adrenoceptor Agonist, in Overactive Bladder

(2012) Christopher R. Chapple et al.   EUROPEAN UROLOGY

Pharmacokinetics and toxicity of antimuscarinic drugs for overactive bladder treatment in females

(2012) Umberto Leone Roberti Maggiore et al.   Expert Opinion on Drug Metabolism & Toxicology

Functional M3 cholinoreceptors are present in pacemaker and working myocardium of murine heart

(2012) Denis V. Abramochkin et al.   PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY

Presence of central nervous system, cardiovascular and overall co-morbidity burden in patients with overactive bladder disorder in a real-world setting

(2011) Carl V. Asche et al.   BJU INTERNATIONAL

Systematic review of overactive bladder therapy in females

(2011) Linda Cardozo   CUAJ-Canadian Urological Association Journal

The influence of propiverine hydrochloride on cardiac repolarization in healthy women and cardiac male patients

(2011) F. Donath et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Comparisons of urodynamic effects, therapeutic efficacy and safety of solifenacin versus tolterodine for female overactive bladder syndrome

(2011) Sheng-Mou Hsiao et al.   JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH

Cardiac effects of muscarinic receptor antagonists used for voiding dysfunction

(2010) Karl-Erik Andersson et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Drug-induced hERG Block and Long QT Syndrome

(2010) Harry J. Witchel   Cardiovascular Therapeutics

Dynamic Progression of Overactive Bladder and Urinary Incontinence Symptoms: A Systematic Review

(2010) Debra E. Irwin et al.   EUROPEAN UROLOGY

The effect of tolterodine 4 and 8 mg on the heart rate variability in healthy subjects

(2010) Maya Schiffers et al.   WORLD JOURNAL OF UROLOGY

A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder

(2009) Yukio Homma et al.   INTERNATIONAL JOURNAL OF UROLOGY

An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction

(2009) Bernard T. Haylen et al.   INTERNATIONAL UROGYNECOLOGY JOURNAL

QT prolongation and torsade de pointes associated with solifenacin in an 81-year-old woman

(2008) Hiroshi Asajima et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Differential Pharmacological Effects of Antimuscarinic Drugs on Heart Rate: A Randomized, Placebo-controlled, Double-blind, Crossover Study With Tolterodine and Darifenacin in Healthy Participants ≥50 Years

(2008) Brian Olshansky et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS